This brief guide is designed as a primer to educate health care providers and partners in sexual health about the need for increased targeted screening and testing among high risk populations and to discuss the implications of the first ever rapid syphilis test (RST) approved by the Food and Drug Administration for use in the United States and CLIA waived for broader use.

The Food and Drug Administration (FDA) has approved a CLIA (Clinical Laboratory Improvement Amendments) waiver for Syphilis Health Check™, the first rapid syphilis (RST) test to receive a waiver for use outside of traditional laboratory settings.  Click above to learn more about this game-changing test.